<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03059992</url>
  </required_header>
  <id_info>
    <org_study_id>SCY-078-301</org_study_id>
    <secondary_id>2017-000381-29</secondary_id>
    <nct_id>NCT03059992</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment</brief_title>
  <acronym>FURI</acronym>
  <official_title>Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 (Ibrexafungerp) in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scynexis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scynexis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy&#xD;
      and safety of ibrexafungerp (SCY-078) in patients ≥ 18 years of age with a documented fungal&#xD;
      disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC) antifungal&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open label, non-comparator, single arm study to evaluate the efficacy&#xD;
      and safety of ibrexafungerp in patients ≥ 18 years of age with a documented invasive and/or&#xD;
      severe fungal disease that has been intolerant or refractory (rIFI) to Standard of Care (SoC)&#xD;
      antifungal treatment. Patients will be treated with ibrexafungerp for up to 180 days.&#xD;
      Treatment beyond 180 days and combination therapy with other antifungal agents may be allowed&#xD;
      under special circumstances to be agreed upon by the Investigator and the Sponsor.&#xD;
&#xD;
      Subjects must have a proven or probable fungal disease and meet all study criteria to be&#xD;
      considered for enrollment. Eligible subjects must also have documented evidence of failure&#xD;
      of, intolerance to, or toxicity related to a currently approved SoC antifungal treatment.&#xD;
&#xD;
      Subjects will also be considered for enrollment if they have an eligible fungal disease and,&#xD;
      in the judgement of the investigator, the subject cannot receive approved oral antifungal&#xD;
      options (e.g. susceptibility of the organism or risk for drug-drug interactions) and a&#xD;
      continued IV antifungal therapy is not desirable or feasible due to clinical or logistical&#xD;
      circumstances.&#xD;
&#xD;
      Following a screening visit, there will be up to 15 treatment visits, a follow-up visit and 2&#xD;
      follow-up contacts.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open label, non-comparator, single arm</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Global Response</measure>
    <time_frame>Up to 180 days of study treatment</time_frame>
    <description>The proportion of subjects with a complete or partial Global Response (GR) at the End of Treatment Visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Recurrence of Baseline Fungal Infection</measure>
    <time_frame>up to 42 days after end of study treatment</time_frame>
    <description>The proportion of subjects with a recurrence of the baseline fungal infectoin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of survival</measure>
    <time_frame>Day 42, Day 84</time_frame>
    <description>Proportion of surviving subjects</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Invasive Candidiasis</condition>
  <condition>Mucocutaneous Candidiasis</condition>
  <condition>Coccidioidomycosis</condition>
  <condition>Histoplasmosis</condition>
  <condition>Blastomycosis</condition>
  <condition>Chronic Pulmonary Aspergillosis</condition>
  <condition>Allergic Bronchopulmonary Aspergillosis</condition>
  <condition>Invasive Pulmonary Aspergillosis</condition>
  <condition>Recurrent Vulvovaginal Candidiasis</condition>
  <condition>Other Emerging Fungi</condition>
  <arm_group>
    <arm_group_label>Ibrexafungerp (SCY-078)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrexafungerp (SCY-078), orally administered QD for up to 180 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrexafungerp</intervention_name>
    <description>Experimental Study Drug</description>
    <arm_group_label>Ibrexafungerp (SCY-078)</arm_group_label>
    <other_name>SCY-078</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Must have a documented eligible invasive and/or severe fungal disease that is&#xD;
             refractory or intolerant to Standard-of-Care treatment&#xD;
&#xD;
          2. Be able to tolerate medication orally or through a nasogastric (NG) tube or&#xD;
             percutaneous endoscopic gastrostomy (PEG) tube&#xD;
&#xD;
          3. Be able to understand and sign a written informed consent form (ICF), which must be&#xD;
             obtained prior to treatment and any study-related procedures.&#xD;
&#xD;
          4. Be able to understand and sign a consent or authorization form which shall permit the&#xD;
             use, disclosure and transfer of the subject's personal health information. (e.g., in&#xD;
             the U.S. HIPAA Authorization form).&#xD;
&#xD;
          5. Be able to understand and follow all study-related procedures including study drug&#xD;
             administration.&#xD;
&#xD;
          6. Agree to use a medically acceptable method of contraception while receiving&#xD;
             protocol-assigned product.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. An invasive fungal disease with CNS involvement.&#xD;
&#xD;
          2. Subject has an inappropriately controlled fungal disease source (e.g., persistent&#xD;
             catheters that cannot be removed and are likely the source of infection).&#xD;
&#xD;
          3. Subject is hemodynamically unstable, requiring vasopressor medication for blood&#xD;
             pressure support.&#xD;
&#xD;
          4. A life expectancy &lt; 30 days.&#xD;
&#xD;
          5. Subject with abnormal liver test parameters: aspartate aminotransferase (AST), alanine&#xD;
             aminotransferase (ALT) &gt;10 x the upper limit of normal (ULN), and/or total bilirubin &gt;&#xD;
             5 x ULN.&#xD;
&#xD;
          6. Subject is pregnant or lactating.&#xD;
&#xD;
          7. Subject has used an investigational drug within 30 days prior to the baseline visit.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Angulo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nkechi Azie, MD</last_name>
    <phone>201-688-2243</phone>
    <email>nkechi.azie@scynexis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristin Bennett</last_name>
    <phone>201-884-5469</phone>
    <email>kristin.bennett@scynexis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brooke Ratliff</last_name>
      <phone>205-996-4046</phone>
      <email>cratliff@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Pappas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasmeen Rezaishad</last_name>
      <phone>916-734-8101</phone>
      <email>yarezaishad@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>George Thomposn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delaney Morris</last_name>
      <phone>404-712-7194</phone>
      <email>delaney.m.johnson@emory.edu</email>
    </contact>
    <investigator>
      <last_name>George Lyon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aprile Osborn</last_name>
      <phone>706-721-0309</phone>
      <email>aosborn@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>Jose Vazquez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Silverman</last_name>
      <phone>617-525-8014</phone>
      <email>esilverman2@bwh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen Walsh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norman Olbrich</last_name>
      <phone>734-615-4383</phone>
      <email>onorman@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Marisa Miceli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Woznicki</last_name>
    </contact>
    <investigator>
      <last_name>Jack Sobel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Casey Dahl</last_name>
      <phone>612-626-3798</phone>
      <email>dahl0465@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Jo-Anne Young, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ella Nadarevic</last_name>
      <phone>319-429-6144</phone>
      <email>nadarevic.ella@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Paschalis Vergidis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Hubert</last_name>
      <phone>314-747-1922</phone>
      <email>sarahubert@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Andrej Spec, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Walsh, MD</last_name>
      <phone>212-746-6320</phone>
      <email>thw2003@med.cornell.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nickolas Pickell</last_name>
      <phone>1-212-746-6311</phone>
      <email>nip3004@med.cornell.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Walsh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Munoz</last_name>
      <phone>631-638-0844</phone>
      <email>sebastian.munoz@stonybrookmedicine.edu</email>
    </contact>
    <investigator>
      <last_name>Roderick Go, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Wright</last_name>
      <phone>919-668-5571</phone>
      <email>diane.wright@dm.duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lashaunda Holmes</last_name>
      <phone>336-716-4267</phone>
      <email>laholmes@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>John Sanders, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburg Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kailey Hughes</last_name>
      <phone>412-648-6453</phone>
      <email>hugheskl4@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Minh-Hong Nguyen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8589</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirstie LeDoux</last_name>
      <phone>214-648-9464</phone>
      <email>kirstie.ledoux@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Ricardo LaHoz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehriban Mammadova</last_name>
      <phone>713-500-6761</phone>
      <email>mehriban.mammadova@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Luis Ostrosky-Zeichner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meg Bayless</last_name>
      <phone>608-262-8156</phone>
    </contact>
    <investigator>
      <last_name>David Andes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Graz Department of Internal Medicine, Department of Pulmology, Section for Infectious Disease and Tropical Medicine</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jurgen Prattes</last_name>
      <phone>+43 316 385 30046</phone>
    </contact>
    <investigator>
      <last_name>Robert Krause, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petra Decristoforo</last_name>
      <phone>0049 6676 8716 72722</phone>
      <email>petra.decristoforo@i-med.ac.at</email>
    </contact>
    <investigator>
      <last_name>Günter Weiss, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephan Eschertzhuber, Prof. Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Köln, Klinik I für Innere Medizin</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanna Proske</last_name>
      <phone>0221 478-85504</phone>
      <email>susanna.proske@uk-koeln.de</email>
    </contact>
    <investigator>
      <last_name>Oliver Cornely, Prof MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Klinik für Infektiologie</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerlinde Augustiniak</last_name>
      <phone>0049 201 723 6022</phone>
      <email>gerlinde.augustiniak@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Oliver Witzke, Prof MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt, Department of Internal Medicine II</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franziska Ebeling</last_name>
      <phone>0049 69 6301 6140</phone>
      <email>franziska.ebeling@kgu.de</email>
    </contact>
    <investigator>
      <last_name>Christoph Stephan, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum St. Georg gGmbH Department for Infectious Disease, Tropical Medicine and Nephrology</name>
      <address>
        <city>Leipzig</city>
        <zip>04129</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Schmidt</last_name>
      <phone>0049 341 909 4472</phone>
      <email>ulrike.schmidt@sanktgeorg.de</email>
    </contact>
    <investigator>
      <last_name>Bernhard Ruf, Prof MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum der Universität München, Medizinische Klinik und Poliklinik III</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Illenyi</last_name>
      <phone>0049 89 4400 75211</phone>
      <email>marta.illenyi@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Helmut Ostermann, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center, Department of Medicine Geert Grooteplein Zuid 8</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Bart-Jan Kullberg, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aga Khan University</name>
      <address>
        <city>Karachi</city>
        <zip>74800</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shazia Abrar</last_name>
    </contact>
    <investigator>
      <last_name>Faisal Mahmood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johese Clinical Research</name>
      <address>
        <city>Lyttelton</city>
        <state>Centurion</state>
        <zip>0154</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leh Watkins</last_name>
      <phone>+27 12 942 0825</phone>
      <email>leh@johese.co.za</email>
    </contact>
    <investigator>
      <last_name>Martie Conradie, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Into Research</name>
      <address>
        <city>Groenkloof</city>
        <state>Pretoria</state>
        <zip>0181</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Booysen</last_name>
      <phone>+27 12 460 1160</phone>
      <email>ria@internists.co.za</email>
    </contact>
    <investigator>
      <last_name>Richard S Siebert, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emmed Research</name>
      <address>
        <city>Muckleneuck</city>
        <state>Pretoria</state>
        <zip>0002</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlet Cronjie</last_name>
      <phone>+27 12 343 6844</phone>
      <email>marlet@clinres.co.za</email>
    </contact>
    <investigator>
      <last_name>Johannes Breedt, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Munoz, MD</last_name>
      <phone>0034 914 265 184</phone>
      <email>pmunoz@hggm.es</email>
    </contact>
    <investigator>
      <last_name>Patricia Munoz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Tasias, MD</last_name>
      <phone>0034 96 124 40 00</phone>
      <email>marionatasias@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Josefa Monzón Soriano</last_name>
      <phone>0034 96 124 40 00</phone>
      <phone_ext>440517</phone_ext>
    </contact_backup>
    <investigator>
      <last_name>Maria Tasias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. George's University of London</name>
      <address>
        <city>London</city>
        <zip>SW17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia Azzouzi</last_name>
      <email>nazzouzi@sgul.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Cruddas</last_name>
      <phone>0044 20 8725 3320</phone>
      <email>Elizabeth.Cruddas@stgeorges.nhs.uk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The University of Manchester</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Riina Richardson, MD</last_name>
      <phone>0044 75 459 949 59</phone>
      <email>Riina.Richardson@manchester.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Karen Rhodes</last_name>
      <phone>0044 (0)161 291 5768</phone>
      <email>karen.rhodes@mft.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Riina Richardson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Pakistan</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Davis MR, Donnelley MA, Thompson GR. Ibrexafungerp: A novel oral glucan synthase inhibitor. Med Mycol. 2020 Jul 1;58(5):579-592. doi: 10.1093/mmy/myz083. Review.</citation>
    <PMID>31342066</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 14, 2017</study_first_submitted>
  <study_first_submitted_qc>February 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2017</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Aspergillosis</mesh_term>
    <mesh_term>Candidiasis, Vulvovaginal</mesh_term>
    <mesh_term>Candidiasis, Invasive</mesh_term>
    <mesh_term>Pulmonary Aspergillosis</mesh_term>
    <mesh_term>Histoplasmosis</mesh_term>
    <mesh_term>Invasive Pulmonary Aspergillosis</mesh_term>
    <mesh_term>Aspergillosis, Allergic Bronchopulmonary</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Coccidioidomycosis</mesh_term>
    <mesh_term>Coccidiosis</mesh_term>
    <mesh_term>Blastomycosis</mesh_term>
    <mesh_term>Candidiasis, Chronic Mucocutaneous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibrexafungerp</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

